Changhong Li is the chief scientific officer at Hua Medicine. He has a deep well of experience in drug development with a focus on diabetes. He completed a postdoctoral fellowship at the Children’s Hospital of Philadelphia of the University of Pennsylvania and spent 15 years at the same institution as a scientist and research assistant professor. In 2018, he founded Nanjing AscendRate Pharmaceutical Technology Co., which became a subsidiary of Hua Medicine in 2022.